ClinicalTrials.gg
CompletedNCT07347327Updated Jan 22, 2026

The Effect of Dual-target tACS Combined With Speech Training on Repetition Disorder After Stroke

An interventional study of speech training and real tACS in Aphasia, sponsored by Ke Dong, MD. Completed at 1 site in China. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Ke Dong, MD · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Jan 2023, registered Jan 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Aphasia with a site in China — 10 open to participants now, 10 under way, none of them phase 3. Aphasia · China.

Enrollment
13th of 13
28 · median 50
Started
2023
with 6 others
No phase
13 of 15
10 open now
Registered
13th of 15
by date
Lead sponsor
1 of 15
Ke Dong, MD

Among the 15 studies in Aphasia with a site in China, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is one of 7 that started in 2023, is one of 13 with no phase, and was the 13th registered.

Aphasia

338 studies on the registry are indexed under Aphasia; 93 are open to participants now.

Browse Aphasia studies →

Open to participants now

10 of the 15 studies in Aphasia with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Aphasia studies recruiting now, 30 (45%) set no upper age limit and 11 (17%) stop at 75 or younger; 1 takes children under 18; 16 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Aphasia with a site in China, or all of them as a file.
02

Study summary

This clinical trial aims to study whether dual-target transcranial alternating current stimulation (tACS) applied to the auditory and motor brain region can improve repetition disorder in people with stroke, and to evaluate the safety of tACS. The main goals are to answer the following questions:

  1. Can dual-tACS stimulation of the auditory and motor brain area improve repetition functions in people with aphasia after stroke?
  2. Can it improve the integration of auditory information and speech motor control during communication?

Researchers will compare the effects of real tACS versus sham (placebo) stimulation to see if real stimulation leads to better outcomes in aphasia patients.

Participants will:

  1. Receive one extra 20-minute session of either real or sham tACS each day for 10 days
  2. Attend clinic visits before and after 10-days stimulation for clinical assessments(WAB) and fNIRS recording related brain activity
03

Conditions studied

  • Aphasia

Browse trials for

04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meeting the diagnostic criteria for hemorrhagic or ischemic stroke in the Chinese Guidelines for the Prevention and Treatment of Cerebrovascular Diseases(2nd edition), with the first onset, single hemisphere stroke, and confirmed by CT or MRI,course of diease 1-6 months;
  • Age ranging from 30 to 80 years old;
  • Native language is Mandarin or Cantonese;
  • Right-handed;
  • Diagnosed with aphasia by the Western Aphasia Battery (WAB) scale;
  • Able to cooperate in completing the speech repetition test;
  • Normal hearing.

Exclusion criteria

Exclusion Criteria:

  • Currently receiving non-invasive brain stimulation treatment;
  • Lesions involving the Broca or STG brain regions;
  • History of epilepsy, mental illness,or other neurological or mental disorders;
  • Any for transcranial electrical stimulation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    real group

    dual-target tACS on auditory and motor brain area at a frequency of 8 Hz,with individualized current intensity, delivered for 20 minutes.

    Behavioral: speech training · Other: real tACS

  • Sham comparator
    sham group

    sham tACS except for turning down the current intensity to zero during the 20-minute period, all other parameters are identical to those in real group.

    Behavioral: speech training · Other: sham tACS

Interventions

  • Behavioralspeech training

    speech training(especially repetition training) synchronized with tACS stimulation

  • Otherreal tACS

    dual-target tACS on auditory and motor brain area at a frequency of 8 Hz,with individualized current intensity, delivered for 20 minutes.

  • Othersham tACS

    except for turning down the current intensity to zero during the 20-minute period, all other parameters are identical to those in real group.

06

What researchers measure

Primary outcomes

  1. Western Aphasia Battery (WAB) score

    Western Aphasia Battery (WAB) score:0-100,higher score means better language function

    Time frame: Baseline and 10-days

07

Study locations

1 site
  • Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Dec 2025, 35 months.

Of 183 non-industry interventional studies with no phase under Aphasia, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's 35 months is close to that.

Counting every sponsor, half of 185 studies reached it within 36 months; a quarter within 19 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Jan 16, 2026
StartActual
Jan 1, 2023
Primary completionActual
Dec 26, 2025
CompletionActual
Dec 29, 2025
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07347327
Lead sponsor
Ke Dong, MD
Responsible party
Ke Dong, MD (Principal Investigator, First Affiliated Hospital, Sun Yat-Sen University) — Sponsor-investigator
First posted
Jan 16, 2026
Start date
Jan 1, 2023
Primary completion
Dec 26, 2025
Completion
Dec 29, 2025
Last update
Jan 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion